Copy to clipboard 
Zimmer Biomet reported 2Q25 orthopedic sales of $2 billion, up 7% compared to the second quarter of 2024. For the first half of 2025, the company generated $3.9 billion in orthopedic sales, up 4% compared to the prior period.
The company turned in a strong quarter despite strong comps from the prior year and delayed international tender orders that got bumped to the third quarter. Zimmer Biomet is very bullish on its opportunities in the second half of the year as its new product cycle further penetrates the market. July was the best month for the company so far in 2025.
Zimmer Biomet said the integration of Paragon 28 is going according to plan, and the company moved its lower extremity products to the Paragon 28 commercial team. The model of keeping a cohesive, high-performing team “away from the mothership” could serve as the template for future acquisitions and integrations.
The company’s most recent acquisition of Monogram lays the groundwork for fully autonomous robotics in the future. Zimmer Biomet expects to launch a semi-autonomous version in 2027, at which point the platform will contribute to revenue growth. However, leadership stresses there’s no race or competition among its widening internal portfolio of technologies.
“We look at different pathways to get to leadership in robotics,” said Zimmer Biomet CEO Ivan Tornos. “We felt with data that having the most flexible and comprehensive product suite is the way to go. I do think you’re going to have a lot of surgeons entering the world of robotics. I think one data point that most people miss is that here in the U.S., 80% of surgeons don’t use a robot. And internationally, 90% of surgeons don’t use a robot.”
In U.S. hip replacement, Zimmer Biomet’s Z1 triple taper stem saw roughly 50% of its users convert from competitive systems. The combination of Z1, the HAMMR surgical impactor and Orthogrid AI-driven guidance has meaningfully improved Zimmer Biomet’s hip performance.
While there remains work to be done in U.S. knee replacement, the Persona OsseoTi cementless total knee is driving incremental progress along with early adoption of the Oxford partial cementless knee. According to the company, nearly 50% of those trained on Oxford adopt the system, with 10% being competitive conversions.
The company now expects 2025 reported revenue growth between 6.7% and 7.7%.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $1,481.9 | $1,419.4 | $62.6 | 4.4% |
| Knees | $825.8 | $801.1 | $24.8 | 3.1% |
| Hips | $536.1 | $506.6 | $29.6 | 5.8% |
| Extremities | $120.0 | $111.7 | $8.2 | 7.4% |
| Trauma | $225.7 | $179.3 | $46.3 | 25.8% |
| Sports Medicine | $56.7 | $51.6 | $5.1 | 9.9% |
| Orthobiologics | $39.1 | $37.6 | $1.5 | 4.1% |
| Enabling Technology | $23.9 | $24.1 | ($0.2) | (0.9%) |
| Other | $250.0 | $230.0 | $20.0 | 8.7% |
| Total | $2,077.3 | $1,942.0 | $135.3 | 7% |
| Segment | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $2,887.4 | $2,808.7 | $78.7 | 2.8% |
| Knees | $1,618.8 | $1,589.1 | $29.6 | 1.9% |
| Hips | $1,031.9 | $997.7 | $34.2 | 3.4% |
| Extremities | $236.8 | $221.8 | $14.9 | 6.7% |
| Trauma | $392.4 | $338.6 | $53.8 | 15.9% |
| Sports Medicine | $108.5 | $99.2 | $9.3 | 9.4% |
| Orthobiologics | $72.6 | $70.4 | $2.3 | 3.2% |
| Enabling Technology | $46.3 | $47.7 | ($1.3) | (2.8%) |
| Other | $479.2 | $466.8 | $12.4 | 2.7% |
| Total | $3,986.5 | $3,831.3 | $155.2 | 4% |
Orthopedic Sales by Geography
| Region | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $1,173.6 | $1,106.2 | $67.5 | 6.1% |
| OUS | $903.7 | $835.9 | $67.8 | 8.1% |
| EMEA | $488.2 | $432.4 | $55.8 | 12.9% |
| APAC | $311.6 | $310.3 | $1.3 | 0.4% |
| ROW | $103.9 | $93.2 | $10.8 | 11.6% |
| Total | $2,077.3 | $1,942.0 | $135.3 | 7% |
| Region | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $2,287.2 | $2,205.8 | $81.4 | 3.7% |
| OUS | $1,699.2 | $1,625.5 | $73.7 | 4.5% |
| EMEA | $946.4 | $877.2 | $69.2 | 7.9% |
| APAC | $564.6 | $568.3 | ($3.7) | (0.7%) |
| ROW | $188.3 | $180.0 | $8.3 | 4.6% |
| Total | $3,986.5 | $3,831.3 | $155.2 | 4% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $2,077.3 | |
| Cost of Sales | $592.2 | 28.5% |
| Selling and Admin | $814.8 | 39.2% |
| R & D | $113.3 | 5.5% |
| Other | $404.2 | 19.5% |
| Net Earnings | $152.8 | 7.4% |
Zimmer Biomet reported 2Q25 orthopedic sales of $2 billion, up 7% compared to the second quarter of 2024. For the first half of 2025, the company generated $3.9 billion in orthopedic sales, up 4% compared to the prior period.
The company turned in a strong quarter despite strong comps from the prior year and delayed international tender...
Zimmer Biomet reported 2Q25 orthopedic sales of $2 billion, up 7% compared to the second quarter of 2024. For the first half of 2025, the company generated $3.9 billion in orthopedic sales, up 4% compared to the prior period.
The company turned in a strong quarter despite strong comps from the prior year and delayed international tender orders that got bumped to the third quarter. Zimmer Biomet is very bullish on its opportunities in the second half of the year as its new product cycle further penetrates the market. July was the best month for the company so far in 2025.
Zimmer Biomet said the integration of Paragon 28 is going according to plan, and the company moved its lower extremity products to the Paragon 28 commercial team. The model of keeping a cohesive, high-performing team “away from the mothership” could serve as the template for future acquisitions and integrations.
The company’s most recent acquisition of Monogram lays the groundwork for fully autonomous robotics in the future. Zimmer Biomet expects to launch a semi-autonomous version in 2027, at which point the platform will contribute to revenue growth. However, leadership stresses there’s no race or competition among its widening internal portfolio of technologies.
“We look at different pathways to get to leadership in robotics,” said Zimmer Biomet CEO Ivan Tornos. “We felt with data that having the most flexible and comprehensive product suite is the way to go. I do think you’re going to have a lot of surgeons entering the world of robotics. I think one data point that most people miss is that here in the U.S., 80% of surgeons don’t use a robot. And internationally, 90% of surgeons don’t use a robot.”
In U.S. hip replacement, Zimmer Biomet’s Z1 triple taper stem saw roughly 50% of its users convert from competitive systems. The combination of Z1, the HAMMR surgical impactor and Orthogrid AI-driven guidance has meaningfully improved Zimmer Biomet’s hip performance.
While there remains work to be done in U.S. knee replacement, the Persona OsseoTi cementless total knee is driving incremental progress along with early adoption of the Oxford partial cementless knee. According to the company, nearly 50% of those trained on Oxford adopt the system, with 10% being competitive conversions.
The company now expects 2025 reported revenue growth between 6.7% and 7.7%.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $1,481.9 | $1,419.4 | $62.6 | 4.4% |
| Knees | $825.8 | $801.1 | $24.8 | 3.1% |
| Hips | $536.1 | $506.6 | $29.6 | 5.8% |
| Extremities | $120.0 | $111.7 | $8.2 | 7.4% |
| Trauma | $225.7 | $179.3 | $46.3 | 25.8% |
| Sports Medicine | $56.7 | $51.6 | $5.1 | 9.9% |
| Orthobiologics | $39.1 | $37.6 | $1.5 | 4.1% |
| Enabling Technology | $23.9 | $24.1 | ($0.2) | (0.9%) |
| Other | $250.0 | $230.0 | $20.0 | 8.7% |
| Total | $2,077.3 | $1,942.0 | $135.3 | 7% |
| Segment | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $2,887.4 | $2,808.7 | $78.7 | 2.8% |
| Knees | $1,618.8 | $1,589.1 | $29.6 | 1.9% |
| Hips | $1,031.9 | $997.7 | $34.2 | 3.4% |
| Extremities | $236.8 | $221.8 | $14.9 | 6.7% |
| Trauma | $392.4 | $338.6 | $53.8 | 15.9% |
| Sports Medicine | $108.5 | $99.2 | $9.3 | 9.4% |
| Orthobiologics | $72.6 | $70.4 | $2.3 | 3.2% |
| Enabling Technology | $46.3 | $47.7 | ($1.3) | (2.8%) |
| Other | $479.2 | $466.8 | $12.4 | 2.7% |
| Total | $3,986.5 | $3,831.3 | $155.2 | 4% |
Orthopedic Sales by Geography
| Region | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $1,173.6 | $1,106.2 | $67.5 | 6.1% |
| OUS | $903.7 | $835.9 | $67.8 | 8.1% |
| EMEA | $488.2 | $432.4 | $55.8 | 12.9% |
| APAC | $311.6 | $310.3 | $1.3 | 0.4% |
| ROW | $103.9 | $93.2 | $10.8 | 11.6% |
| Total | $2,077.3 | $1,942.0 | $135.3 | 7% |
| Region | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $2,287.2 | $2,205.8 | $81.4 | 3.7% |
| OUS | $1,699.2 | $1,625.5 | $73.7 | 4.5% |
| EMEA | $946.4 | $877.2 | $69.2 | 7.9% |
| APAC | $564.6 | $568.3 | ($3.7) | (0.7%) |
| ROW | $188.3 | $180.0 | $8.3 | 4.6% |
| Total | $3,986.5 | $3,831.3 | $155.2 | 4% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $2,077.3 | |
| Cost of Sales | $592.2 | 28.5% |
| Selling and Admin | $814.8 | 39.2% |
| R & D | $113.3 | 5.5% |
| Other | $404.2 | 19.5% |
| Net Earnings | $152.8 | 7.4% |
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
